
## ATOPIC DERMATITIS TREATMENT PATHWAY (ADULTS)



The following is applicable to the High Cost Immunomodulator section only.

### **Pathway definitions:**

	Definition	Action	
Primary Failure	Occurs when the response criteria (as defined within the NICE TA) is <b>not fully met</b> when response to treatment is assessed at the time interval  defined within the NICE TA	Move to the NEXT treatment line/mode of action (if one is available)	
Secondary Failure	Occurs when the response to treatment (as defined within the NICE TA) is	Move to the NEXT treatment line/mode of action	
	no longer met	(if one is available)	
Primary intolerance/adverse effects	An occurrence that causes discontinuation of treatment, due to inability to		
	tolerate side-effects of that treatment that occurs during the initial time	Use another option from the SAME treatment line	
	period defined by the NICE TA		
Secondary intolerance/adverse effects	An occurrence that causes discontinuation of treatment, due to inability to	Move to the NEXT treatment line OR discuss at RN	
	tolerate side effects of that treatment that occurs after the initial time	meeting	
	period defined by the NICE TA		
Conception	If conception plans or pregnancy indicate a change of drug is advisable,	Please update via Blueteq accordingly	
	it is agreed that this does not constitute a change in line of treatment		

# Drug choices and length of initial treatment before first review<sup>1</sup>:

Mode of action	Drug	Initial treatment length as specified by NICE TA	NICE TA
IL4 / 23 inhibitor	Dupilumab	16 weeks	<u>TA534</u>
JAK inhibitor (Oral)	Abrocitinib (least costly)	16 weeks	<u>TA814</u>
	Baricitinib	16 weeks	<u>TA681</u>
	Upadacitinib	16 weeks	<u>TA814</u>
IL13 inhibitor	Tralokinumab	16 weeks	<u>TA814</u>
	Lebrikizumab (least costly after 16 weeks)	16 weeks	<u>TA986</u>

### Notes:

- 1. Embedded hyperlinks are either to NICE Clinical Knowledge Summaries, NICE Technical Appraisals <a href="www.nice.org.uk">www.nice.org.uk</a>, or pages within the Surrey Prescribing Advisory Database (res-systems.net)
- 2. If patients on JAK inhibitors need to change therapy due to the MHRA alert<sup>2</sup> issued 26th April 2023, then this would be considered a change within the same treatment line.

### **References:**

- 1) NICE Technical Guidance TA81, TA82, TA534, TA681, TA814 & TA986 Available at https://www.nice.org.uk
- 2) Drug Safety Update. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality. Available at: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- 3) MHRA/CHM advice: Dupilumab (Dupixent®): Risk of ocuLar adverse reactions and need for prompt management (November 2022)

Reviewed: NHS Surrey Heartlands ICB Medicines Resource Unit Input from: Dermatology Network - September 2024

Agreed date: Area Prescribing Committee October 2024 Review date: September 2027